Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

A receptor tyrosine kinase/MALT1 axis promotes hallmarks of cancer in H3K27-altered diffuse midline glioma

Crentsil, Hannah Elizabeth (2024) A receptor tyrosine kinase/MALT1 axis promotes hallmarks of cancer in H3K27-altered diffuse midline glioma. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

[img] PDF (ETD Hannah Crentsil)
Primary Text
Restricted to University of Pittsburgh users only until 14 October 2026.

Download (25MB) | Request a Copy

Abstract

Background: H3K27-altered diffuse midline glioma (DMG) is a devastating pediatric brainstem tumor that affects 200-300 individuals in the US per year. Median survival is 9-11 months, and there are virtually no long-term survivors. Despite decades of clinical trials, radiation therapy remains standard of care, extending survival by 2-3 months. Elucidating the mechanisms that drive H3K27-altered DMG pathogenesis in order to uncover therapeutic vulnerabilities is of critical importance.
Recent studies implicate MALT1 as a potential therapeutic target in gliomas. MALT1 is the effector molecule of the CARMA-BCL10-MALT1 (CBM) signalosome, a cytoplasmic protein complex that drives downstream pro-survival transcriptional activity. MALT1, which possesses scaffolding and protease functions, promotes cell viability, proliferation, and migration/invasion in multiple solid tumor types in response to receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) signaling. We aim to evaluate the hypothesis that MALT1 promotes H3K27-altered DMG cell proliferation and migration in response to RTK activation and represents a therapeutic target in H3K27-altered DMG.
Methods/Results: We screened a panel of H3K27-altered DMG cell lines by Western blot and found that the CBM complex members CARMA3, MALT1 and BCL10 are expressed in H3K27-altered DMG cells. We next demonstrated that MALT1 is proteolytically active in H3K27-altered DMG cell lines. Specifically, we showed that the MALT1 protease substrate HOIL1 is cleaved in DMG cells, and that this cleavage is abrogated by treatment with the MALT1 protease inhibitor MLT-748. We next engineered multiple H3K27-altered DMG cell lines to express dox-inducible MALT1 shRNA in order to assess the impact of MALT1 deficiency on H3K27-altered DMG cell biology. Results from an Oncology Array membrane evaluating expression of over 80 cancer-implicated proteins in HSJD-DIPG-007 DMG cells demonstrate that among all proteins tested, the RTK EGFR demonstrates the greatest decrease in expression following MALT1 knockdown. Subsequent studies indicate the operation of a MALT1-RTK signaling axis in HSJD-DIPG-007 DMG cells, whereby MALT1 knockdown leads to reduced expression of the RTKs EGFR and FGFR1, as well as diminished proliferation in response to EGF and FGF and reduced migration towards EGF. In contrast, MALT1 knockdown does not lead to a phenotypic effect on migration and proliferation of BT245 and SF8628 DMG cell lines, indicating that these effects of MALT1 knockdown are cell line specific. These differences may be due to the distinct mutational profiles of the H3K27-altered DMG cell lines tested.
Conclusions/Future Directions: MALT1 is expressed and proteolytically active in H3K27-altered DMG cells. Our studies implicate MALT1 as a regulator of EGFR and FGFR1 expression and migration/proliferation in response to RTK ligand stimulation in HSJD-DIPG-007 DMG cells. Future studies will evaluate whether MALT1 regulates RTK expression in additional cell lines and cancer types and will determine whether MALT1 knockdown reduces H3K27-altered DMG tumor progression in vivo. As we continue to uncover the specific pathways at work that sensitize some H3K27-altered DMG cells to MALT1 targeting, we hope to determine whether MALT1 represents a potential therapeutic target in a subset of patients with H3K27-altered DMG.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Crentsil, Hannah ElizabethHEB62@pitt.eduHEB620000-0002-2076-0950
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairDeFrances, Mariedefrancesmc@upmc.edu
Thesis AdvisorLucas, Peterlucas.peter@mayo.edu
Thesis AdvisorMcAllister-Lucas, Lindamcallister.linda@mayo.edu
Committee MemberAgnihotri, Sameersameer.agnihotri@gmail.com
Committee MemberHu, Baolibaoli.hu3@chp.edu
Committee MemberZervantonakis, Ioannisioz1@pitt.edu
Date: 14 October 2024
Date Type: Publication
Defense Date: 29 July 2024
Approval Date: 14 October 2024
Submission Date: 12 August 2024
Access Restriction: 2 year -- Restrict access to University of Pittsburgh for a period of 2 years.
Number of Pages: 185
Institution: University of Pittsburgh
Schools and Programs: School of Medicine > Cellular and Molecular Pathology
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: H3K27-altered DMG, MALT1, CBM signalosome, Cancer cell signaling
Date Deposited: 14 Oct 2024 15:55
Last Modified: 14 Oct 2024 15:55
URI: http://d-scholarship.pitt.edu/id/eprint/46918

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item